Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

To Boost Productivity, India’s Advinus, Takeda Team Up For R&D Across Therapies

This article was originally published in PharmAsia News

Executive Summary

Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.

You may also be interested in...



From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India

MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market

Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)

Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel